医疗器械 渠道积淀筑底，自研驱动与战略拓展打开成长空间 可孚医疗（301087.SZ） 证券研究报告/公司深度报告 2026 年 02 月 11 日 | 评级： | 买入（首次） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | | | 营业收入（百万元） | 2,854 | 2,983 | 3,384 | 4,098 | 5,100 | | 分析师：祝嘉琦 | | 增长率 yoy% | -4% | 5% | 13% | 21% | 24% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | 254 | 312 | 359 | 436 | 551 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | -16% | 23% | 15% | 22% | 26% | | | | 每股收益（元） | 1.22 | 1.49 | 1.72 | 2.09 | ...

指数震荡调整，可持续发展信披指南修订发布 ——北交所周报（1.26-1.30） 评级： 增持（维持） 分析师：冯胜 执业证书编号：S0740519050004 Email：fengsheng@zts.com.cn 分析师：向兰 执业证书编号：S0740525020002 Email：xianglan@zts.com.cn 北交所基本状况 | 上市公司数 | 292 | | --- | --- | | 行业总市值(亿元) | 9,363.02 | | 行业流通市值(亿元) | 5,802.61 | 最近一年北证 50 VS 沪深 300 北交所 证券研究报告/行业定期报告 2026 年 02 月 10 日 报告摘要 北交所行情概览： 1）整体行情：截至 2026 年 1 月 30 日，北证成份股 292 个，平均市值 32.07 亿元。 本周（2026 年 1 月 26 日-2026 年 1 月 30 日，下同）北证 50 指数涨跌幅-3.59%，收 盘 1531.55 点；同期沪深 300、创业板指、科创 50 涨跌幅分别为 0.08%、-0.09%、 -2.85%。本周北交所日均成交额为 287.31 亿元 ...

指数震荡调整，可持续发展信披指南修订发布 ——北交所周报（1.26-1.30） 评级： 增持（维持） 分析师：冯胜 Email：fengsheng@zts.com.cn 分析师：向兰 执业证书编号：S0740525020002 Email：xianglan@zts.com.cn 北交所基本状况 | 上市公司数 | 292 | | --- | --- | | 行业总市值(亿元) | 9,363.02 | | 行业流通市值(亿元) | 5,802.61 | 最近一年北证 50 VS 沪深 300 北交所 证券研究报告/行业定期报告 2026 年 02 月 10 日 执业证书编号：S0740519050004 报告摘要 北交所行情概览： 1）整体行情：截至 2026 年 1 月 30 日，北证成份股 292 个，平均市值 32.07 亿元。 本周（2026 年 1 月 26 日-2026 年 1 月 30 日，下同）北证 50 指数涨跌幅-3.59%，收 盘 1531.55 点；同期沪深 300、创业板指、科创 50 涨跌幅分别为 0.08%、-0.09%、 -2.85%。本周北交所日均成交额为 287.31 亿元 ...

详解 2025 年理财年度报告： 规模稳步增长，增配现金类资产 评级： 增持（维持） 分析师：戴志锋 执业证书编号：S0740517030004 Email：daizf@zts.com.cn 分析师：邓美君 执业证书编号：S0740519050002 Email：dengmj@zts.com.cn 分析师：陈程 执业证书编号：S0740525110001 Email：chencheng07@zts.com.cn 基本状况 上市公司数 42 行业总市值(亿元) 146,116.35 行业流通市值(亿元) 139,898.72 报告摘要 相关报告 业绩增速有望稳中向好，资产质量持 续优化》2026-02-08 贷款 5.1-5.25 万亿元，社融增速为 8.3%》2026-02-07 门 红 奠 定 全 年 业 绩 稳 健 基 调 》 2026-01-31 银行 证券研究报告/行业点评报告 2026 年 02 月 09 日 风险提示事件：经济下滑超预期，经济恢复不及预期，数据更新不及时。 请务必阅读正文之后的重要声明部分 理财产品存续规模为 33.29 万亿元，同比增长 11.2%，全年合计增量为 3.34 万亿 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector is experiencing a rebound in bottom assets, particularly in traditional Chinese medicine, medical services, and pharmacies, driven by market rotation and price increase expectations in raw materials [7][11] - The report emphasizes the importance of focusing on bottom assets that are expected to see turning points and well-adjusted innovative drug sectors, with a positive outlook on growth directions representing the future of the pharmaceutical industry [11] - Key themes include continuous attention to pharmaceutical and medical AI+, as well as significant data updates expected from major conferences in 2026 [11] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 3.28% compared to the Shanghai Composite's 0.29% since the beginning of 2026 [26] - The report notes that the pharmaceutical sector's valuation is currently at 22.8 times PE, with a premium of 11.7% over the overall A-share market [30] Key Company Performance - Recommended stocks for February include WuXi Biologics, Tigermed, and others, with a focus on companies that have shown significant pipeline progress or business development expectations [8][36] - The report highlights the performance of companies like Guangsheng Tang and Nuo Cheng Jian Hua, which have made notable advancements in their core pipelines [36] Industry Trends - The report discusses the trend of combining IO plus therapies and the development of new targets in the dual antibody space, indicating a growing trend in clinical applications [12][14] - Attention is drawn to the ADC (Antibody-Drug Conjugate) sector, particularly large indication FIC (First-in-Class) products and the potential for new indications to enhance overseas mapping [14][17] - The report also highlights the evolving landscape in blood cancers, with new therapies showing promise in previously underserved areas [20]

发明"负债行为框架" 证券研究报告/固收专题报告 2026 年 02 月 09 日 分析师：林莎 执业证书编号：S0740525060004 Email：linsha@zts.com.cn 分析师：吕品 执业证书编号：S0740525060003 Email：lvpin@zts.com.cn 报告摘要 今年元旦以来，我们明显能看到，A 股正在经历负债行为进一步变化、资产端多方向 催化、以及债券开门红行情转移至权益这三个因子的叠加共振。 如何从负债端的视角进行理解？ 第一，牛市的底气来自于定期存款集中到期以及存款活性化。"活期-理财-分红险-公 募基金"，基于投资回报率的视角，吸引力逐级抬升，拥抱权益资产的程度也显著上 升。 请务必阅读正文之后的重要声明部分 第二，分红险可作为高息存款到期后的替代。当前定期存款利率低于分红险的"保证 收益"部分，银保渠道将部分到期不续存的定期存款承接至分红险。 第三，固收不够，需要通过加权益来增厚收益。理财规模迅速扩张，资产端的收益却 面临巨大挑战，单纯依赖债基投资已难以满足理财产品的业绩诉求，倒逼资金向权益 资产寻求弹性。理财产品结构趋向含权理财，"+"的部分正在从红利切换到 ...

【中泰研究丨晨会聚焦】固收吕品：多空互加筹码，债市迎来 "验牌时刻" 证券研究报告/晨会聚焦 2026 年 02 月 09 日 分析师：戴志锋 2、《【中泰研究丨晨会聚焦】医药祝嘉 琦：战略重视原料药板块，价格修复 +新业务增量；积极把握医药底部机 会》2026-02-04 3、《【中泰研究丨晨会聚焦】军工陈鼎 如：Space X 再申请百万颗卫星，商 业航天关注度持续提升》2026-02-03 今日预览 今日重点>> 【固收】吕品：多空互加筹码，债市迎来"验牌时刻" 执业证书编号：S0740517030004 Email：daizf@zts.com.cn 欢迎关注中泰研究所订阅号 晨报内容回顾 1、《【中泰研究丨晨会聚焦】固收林 莎：如何在定位和投资上做好一只"固 收+"——基金四季报详细拆解》 2026-02-06 【食品饮料】何长天：快餐市场重焕生机，产品创新增时运营 研究分享>> 【固收】吕品：信用债类 ETF 持续净流出 请务必阅读正文之后的重要声明部分 今日重点 【固收】吕品：多空互加筹码，债市迎来"验牌时刻" 近两周以来，债市的行情不断修复。尤其是以二永、10 年内期限为代表的配置型品种来说，债 ...

Report Summary 1. Report Industry Investment Rating No industry investment rating information is provided in the report. 2. Core Viewpoints - Last week, the ChinaBond New Composite Index rose 0.08% throughout the week; short - term and medium - long - term pure bond funds rose 0.01% respectively; the CSI AAA Sci - tech Innovation Bond Index and the SSE Benchmark Market - making Corporate Bond Index rose 0.03% respectively [2]. - As of February 6, 2026, bond - type ETFs had a net outflow of 4.075 billion yuan in the past week, with interest - rate, credit, and convertible - bond ETFs having net inflows of 1.745 billion yuan, net outflows of 6.72 billion yuan, and net inflows of 0.9 billion yuan respectively [4]. - Overall, the net values of various types of bond ETF products generally rose last week. As of February 6, 2026, the 30 - year Treasury Bond ETF Boshi performed well, rising 0.74% for the week [5]. 3. Summary by Relevant Catalogs 3.1 Funds Flow - As of February 6, 2026, bond - type ETFs had a net outflow of 4.075 billion yuan in the past week. Interest - rate, credit, and convertible - bond ETFs had net inflows of 1.745 billion yuan, net outflows of 6.72 billion yuan, and net inflows of 0.9 billion yuan respectively. Among credit - type ETFs, short - term financing, corporate bonds, and urban investment bonds had net inflows of 3.274 billion yuan, 0.016 billion yuan, and 0.283 billion yuan respectively, while market - making credit bonds had a net outflow of 2.384 billion yuan, and sci - tech innovation bonds had a net outflow of 7.908 billion yuan. Since 2025, interest - rate, credit, and convertible - bond ETFs have had cumulative net inflows of 53.805 billion yuan, 459.605 billion yuan, and 33.807 billion yuan respectively, totaling 547.217 billion yuan [4]. 3.2 Net Value Performance - Overall, the net values of various types of bond ETF products generally rose last week. As of February 6, 2026, the 30 - year Treasury Bond ETF Boshi performed well, rising 0.74% for the week; the Treasury Bond ETF Huaxia rose 0.23%, and the Policy Financial Bond ETF rose 0.22%. The Convertible Bond ETF and the SSE Convertible Bond ETF fell 0.02% and 0.12% respectively last week [5]. 3.3 Performance of Credit Bond ETFs and Sci - tech Innovation Bond ETFs - As of February 6, 2026, the median unit net values of credit bond ETFs and sci - tech innovation bond ETFs were 1.0148 and 1.0026 respectively, rising 0.02% and 0.01% for the week. Among credit bond ETFs, the Credit Bond ETF Boshi performed relatively well, rising 0.03% for the week. Among sci - tech innovation bond ETFs, the Sci - tech Innovation Bond ETF Dacheng and the Sci - tech Innovation Bond ETF Yongying performed relatively well. As of February 6, 2026, the median discount rate of credit bond ETFs was 16BP, and that of sci - tech innovation bond ETFs was 17BP [6]. 3.4 Duration Tracking of Credit - type ETFs - As of February 6, 2026, the holding durations of short - term financing ETFs, corporate bond ETFs, and urban investment bond ETFs were 0.31 years, 1.90 years, and 2.08 years respectively. Among market - making credit bond ETFs, the median holding durations of products tracking the Shanghai Market - making Corporate Bond Index and the Shenzhen Market - making Corporate Bond Index were 3.57 years and 2.74 years respectively. Among sci - tech innovation bond ETFs, the median holding durations of products tracking the AAA Sci - tech Innovation Bond Index, the Shanghai AAA Sci - tech Innovation Bond Index, and the Shenzhen AAA Sci - tech Innovation Bond Index were 3.28 years, 3.18 years, and 3.14 years respectively [7].

Investment Rating - The report maintains an "Overweight" rating for the light industry manufacturing and textile apparel sectors [1]. Core Insights - Ralph Lauren's Q3 2026 performance exceeded expectations with a 12% year-on-year revenue increase and a 21.6% rise in net profit, driven by strong growth in China and a robust direct-to-consumer channel [5]. - The Milan Winter Olympics is expected to enhance the visibility and demand for sports brands, particularly benefiting companies like Li Ning and Anta, which have established partnerships for the event [6]. - The report highlights the resilience of the Chinese market and the ongoing premiumization of brands, indicating a shift from mass luxury to top-tier luxury business models [5][6]. Summary by Sections Company Performance - Ralph Lauren's revenue growth was over 30% in China, with North America and Europe also showing positive trends [5]. - Tapestry reported a 14% increase in net sales, with significant growth in its Coach brand [5]. Market Trends - The light industry manufacturing index rose by 0.96%, ranking 8th among 28 industries, while the textile apparel index increased by 1.32%, ranking 6th [11]. - The report notes a positive outlook for sports and outdoor products sales due to major sporting events in 2026, including the Winter Olympics and World Cup [6]. Sector Analysis - The report suggests focusing on companies with clear Olympic rights and product strategies, such as Anta and Li Ning, as they prepare for significant events [6]. - In the textile manufacturing sector, Uniqlo's FY26Q1 performance was above expectations, with a 20.3% increase in overseas markets [6]. Investment Recommendations - The report recommends monitoring companies like Bubble Mart for their ability to innovate and maintain market confidence through product launches and share buybacks [6]. - It also suggests looking into the AI eyewear market, highlighting the potential for growth as AI technology becomes more integrated into consumer products [6].